Cited by 853Health Systems, Economic Evaluations, Quality of LifePharmaceutical Economics and PolicyGlobal Health Care Issues

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Thresholds for the cost–effectiveness of interventions: alternative approaches

Open access

Marseille, Elliot, Larson, Bruce, Kazi, Dhruv S, Kahn, James G, Rosen, Sydney·2015·Bulletin of the World Health Organization

DOI 10.2471/blt.14.138206PMC PMC4339959

Open this paper in CoChat — free account

Abstract

Many countries use the cost-effectiveness thresholds recommended by the World Health Organization's Choosing Interventions that are Cost-Effective project (WHO-CHOICE) when evaluating health interventions. This project sets the threshold for cost-effectiveness as the cost of the intervention per disability-adjusted life-year (DALY) averted less than three times the country's annual gross domestic product (GDP) per capita. Highly cost-effective interventions are defined as meeting a threshold per DALY averted of once the annual GDP per capita. We argue that reliance on these thresholds reduces the value of cost-effectiveness analyses and makes such analyses too blunt to be useful for most decision-making in the field of public health. Use of these thresholds has little theoretical justification, skirts the difficult but necessary ranking of the relative values of locally-applicable interventions and omits any consideration of what is truly affordable. The WHO-CHOICE thresholds set such a low bar for cost-effectiveness that very few interventions with evidence of efficacy can be ruled out. The thresholds have little value in assessing the trade-offs that decision-makers must confront. We present alternative approaches for applying cost-effectiveness criteria to choices in the allocation of health-care resources.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2471/blt.14.138206

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
The World Health Report 2002 - Reducing Risks, Promoting Healthy Life
Available, N. A. N. (2003) · Education for Health · doi:10.1080/1357628031000116808 · Cited by 6,078
Methods for the economic evaluation of health care programmes
Wilson, S. (1987) · Journal of Epidemiology & Community Health · doi:10.1136/jech.41.4.355-a · Cited by 4,312
Cost-Benefit Analysis: Concepts and Practice
Boardman, A. E., Greenberg, D. H., Vining, A. R., & Weimer, D. L. (1996) · Cited by 1,920
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A. H., Mauskopf, J., Loder, E., et al. (2013) · BMJ · doi:10.1136/bmj.f1049 · Cited by 1,776
Methods for the economic evaluation of health care programmes, 3rd ed
Adamiak, G. T. (2006) · PubMed Central · Cited by 953
The Value of Life and the Rise in Health Spending
Hall, R. E., & Jones, C. I. (2007) · The Quarterly Journal of Economics · doi:10.1162/qjec.122.1.39 · Cited by 924
Willingness to Pay for a Quality-adjusted Life Year: In Search of a Standard
Hirth, R. A., Chernew, M. E., Miller, E., Fendrick, A. M., & Weissert, W. G. (2000) · Medical Decision Making · doi:10.1177/0272989x0002000310 · Cited by 850
Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?
Thorlund, K., Devereaux, P. J., Wetterslev, J., Guyatt, G. H., Ioannidis, J. P. A., Thabane, L., Gluud, L. L., Als-Nielsen, B. E. T., & Gluud, C. N. (2008) · International Journal of Epidemiology · doi:10.1093/ije/dyn179 · Cited by 834
Cost-effectiveness analysis.
Robinson, R. (1993) · BMJ · doi:10.1136/bmj.307.6907.793 · Cited by 819

Flagged first, then by citations

Show all 42 references

Sorted by citations

Items 201–300 of 853

Research Techniques Made Simple: Cost-Effectiveness Analysis
Shi, C. R., & Nambudiri, V. E. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.03.004 · Cited by 26
Cost-effectiveness analysis of malaria interventions using disability adjusted life years: a systematic review
Gunda, R., & Chimbari, M. J. (2017) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-017-0072-9 · Cited by 23
When Is The Price Of A Drug Unjust? The Average Lifetime Earnings Standard
Emanuel, E. (2019) · Health Affairs · doi:10.1377/hlthaff.2018.05052 · Cited by 23
Assessing the impact of aggregating disease stage data in model predictions of human African trypanosomiasis transmission and control activities in Bandundu province (DRC)
Castaño, S., Ndeffo-Mbah, M. L., Rock, K. S., Palmer, C., Knock, E., Miaka, E. M., Ndung’u, J. M., Torr, S. J., Verlé, P., Spencer, S. E. F., et al. (2020) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0007976 · Cited by 23
Cost-effectiveness of apixaban for prevention of venous thromboembolic events in patients after gynecologic cancer surgery
Glickman, A., Brennecke, A., Tayebnejad, A., Matsuo, K., Guntupalli, S. R., & Sheeder, J. L. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.07.096 · Cited by 23
First-line Treatment with Empagliflozin and Metformin Combination Versus Standard Care for Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease in Qatar. A Cost-Effectiveness Analysis
Abushanab, D., Al‐Badriyeh, D., Liew, D., & Ademi, Z. (2021) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2021.100852 · Cited by 24
2025 AHA/ACC Statement on Cost/Value Methodology in Clinical Practice Guidelines (Update From 2014 Statement): A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Kazi, D. S., Abdullah, A. R., Arnold, S. V., Basu, A., Bellows, B. K., Breathett, K. K., Chew, D. S., Cohen, D. J., DeJong, C., Heidenreich, P. A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001377 · Cited by 22
Self-citation
Cost-effectiveness of post-landing latent tuberculosis infection control strategies in new migrants to Canada
Campbell, J. R., Johnston, J. C., Sadatsafavi, M., Cook, V. J., Elwood, R. K., & Marra, F. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186778 · Cited by 20
Cost-Effectiveness of Peer-Delivered HIV Self-Tests for MSM in Uganda
Okoboi, S., Castelnuovo, B., Geertruyden, J. V., Lazarus, O., Vu, L., Kalibala, S., Kamara, Y., Ochanda, P. N., King, R. L., & Mujugira, A. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.651325 · Cited by 21
Cost-Utility Analysis of Add-on Dapagliflozin in Heart Failure with Reduced Ejection Fraction in the Philippines
Mendoza, V. L., Tumanan-Mendoza, B. A., & Punzalan, F. E. R. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13583 · Cited by 22
Cost-Effectiveness of Lay First Responders Addressing Road Traffic Injury in Sub-Saharan Africa
Delaney, P. G., Eisner, Z. J., Bustos, A., Hancock, C. J., Thullah, A. H., Jayaraman, S., & Raghavendran, K. (2021) · Journal of Surgical Research · doi:10.1016/j.jss.2021.08.032 · Cited by 22
Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma
Kambhampati, S., Saumoy, M., Schneider, Y., Pak, S., Budde, L. E., Mei, M. G., Siddiqi, T., Popplewell, L. L., Wen, Y.-P., Zain, J. M., et al. (2022) · Blood · doi:10.1182/blood.2022016624 · Cited by 22
Self-citation
Cost-effectiveness analysis of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal squamous-cell carcinoma in China
Liu, S., Dou, L., & Li, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1055727 · Cited by 22
Increasing the Take-Up of Public Health Services: An At-Scale Experiment on Digital Government
Gallegos, S., Roseth, B., Cuesta, A., & Sánchez, M. A. (2022) · Journal of Public Economics · doi:10.1016/j.jpubeco.2023.104975 · Cited by 22
Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results
Yun, H., Kim, J. W., Gandhe, A., Nelson, B., Hu, J. C., Gulani, V., Margolis, D., Schackman, B. R., & Jalali, A. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.44856 · Cited by 22
Human health benefits and burdens of a pharmaceutical treatment: Discussion of a conceptual integrated approach
Debaveye, S., Soete, W. D., Meester, S. D., Vandijck, D. M., Heirman, B., Kavanagh, S., & Dewulf, J. P. (2015) · Environmental Research · doi:10.1016/j.envres.2015.10.027 · Cited by 22
Cost‐Effectiveness Analysis of Second‐Line Chemotherapy Agents for Advanced Gastric Cancer
Lam, S. W., Wai, M., Lau, J. E., McNamara, M. J., Earl, M. A., & Udeh, B. L. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1870 · Cited by 22
Cost-Effectiveness Thresholds: Guiding Health Care Spending for Population Health Improvement
Revill, P. A., Ochalek, J., Lomas, J. R. S., Nakamura, R., Woods, B. S., Rollinger, A., Suhrcke, M., Sculpher, M. J., & Claxton, K. (2020) · World Scientific series in global healthcare economics and public policy · doi:10.1142/9789813272378_0003 · Cited by 22
Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey
Smedt, D. D., Annemans, L., Backer, G. D., Kotseva, K., Rydén, L., Wood, D., Amouyel, P., Bruthans, J., Cífková, R., SUTTER, J. D., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.06.104 · Cited by 22
Cardiovascular disease risk and comparison of different strategies for blood pressure management in rural India
Praveen, D., Peiris, D., MacMahon, S. W., Mogulluru, K., Raghu, A., Rodgers, A., Chilappagari, S., Prabhakaran, D., Clifford, G. D., Maulik, P. K., et al. (2018) · BMC Public Health · doi:10.1186/s12889-018-6142-x · Cited by 22
Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals
Gountas, I., Sypsa, V., Papatheodoridis, G., Souliotis, K. N., Athanasakis, K., Razavi, H. A., & Hatzakis, A. E. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i11.1327 · Cited by 22
Economic evaluations of onchocerciasis interventions: a systematic review and research needs
Turner, H. C., Walker, M., Pion, S. D. S., McFarland, D. A., Bundy, D. A. P., & Basáñez, M.-G. (2019) · Tropical Medicine & International Health · doi:10.1111/tmi.13241 · Cited by 22
Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research
Ochalek, J., & Lomas, J. R. S. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.12.002 · Cited by 23
How much might a society spend on life-saving interventions at different ages while remaining cost-effective? A case study in a country with detailed data
Kvizhinadze, G., Wilson, N., Nair, N. P., McLeod, M., & Blakely, T. A. (2015) · Population Health Metrics · doi:10.1186/s12963-015-0052-2 · Cited by 22
In the Era of Cost-Effectiveness Analysis, Affordability Is a Limiting Factor for Patients' Access to Innovative Cancer Treatments
Aguiar, P. N., Adashek, J. J., Roitberg, F., Barreto, C. M. N., del Giglio, A., & Junior, G. L. L. (2019) · Value in Health Regional Issues · doi:10.1016/j.vhri.2018.12.003 · Cited by 22
Strategies for the prevention of perinatal hepatitis B transmission in a marginalized population on the Thailand-Myanmar border: a cost-effectiveness analysis
Devine, A., Harvey, R. C., Min, A. M., Gilder, M. E., Paw, M. K., Kang, J., Watts, I. V. C., Hanboonkunupakarn, B., Nosten, F. H., & McGready, R. M. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2660-x · Cited by 21
The health economics of cholera: A systematic review
Hsiao, A., Hall, A. H., Mogasale, V., & Quentin, W. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.05.120 · Cited by 21
Cost-effectiveness of Low-complexity Screening Tests in Community-based Case-finding for Tuberculosis
Brümmer, L. E., Thompson, R. R., Malhotra, A., Shrestha, S., Kendall, E. A., Andrews, J. R., Phillips, P. P. J., Nahid, P., Cattamanchi, A., Marx, F. M., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad501 · Cited by 21
Cost-effectiveness of interventions for HIV/AIDS, malaria, syphilis, and tuberculosis in 128 countries: a meta-regression analysis
Silke, F., Earl, L., Hsu, J., Janko, M., Joffe, J., Memetova, A., Michael, D., Zheng, P., Aravkin, A. Y., Murray, C. J. L., et al. (2024) · The Lancet Global Health · doi:10.1016/s2214-109x(24)00181-5 · Cited by 21
A compensating income variation approach to valuing 34 health conditions in Iceland
Ásgeirsdóttir, T. L., Birgisdóttir, K. H., Ólafsdóttir, Þ., & Olafsson, S. P. (2017) · Economics & Human Biology · doi:10.1016/j.ehb.2017.06.001 · Cited by 21
Cost-effectiveness of Paclitaxel + Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing After First-line Chemotherapy in Japan
Saito, S., Muneoka, Y., Ishikawa, T., & Akazawa, K. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.10.017 · Cited by 21
A dynamic, modifiable model for estimating cost‐effectiveness of smoking cessation interventions in pregnancy: application to an RCT of self‐help delivered by text message
Jones, M., Smith, M. D., Lewis, S., Parrott, S., & Coleman, T. J. (2018) · Addiction · doi:10.1111/add.14476 · Cited by 22
Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia
Malkin, S. J. P., Russel-Szymczyk, M., Liidemann, G., Volke, V., & Hunt, B. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0542-x · Cited by 21
Cost-effectiveness modelling studies of all preventive measures against rabies: A systematic review
Anothaisintawee, T., Genuino, A. J., Thavorncharoensap, M., Youngkong, S., Rattanavipapong, W., Meeyai, A. C., & Chaikledkaew, U. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.11.071 · Cited by 21
Economic Value of Vaccines to Address the COVID-19 Pandemic in Hong Kong: A Cost-Effectiveness Analysis
Xiong, X., Li, V. J., Huang, B., Tam, T., Hong, Y., Chong, K. C., & Huo, Z. (2022) · Vaccines · doi:10.3390/vaccines10040495 · Cited by 20
Economic Evaluation of Health Behavior Interventions to Prevent and Manage Type 2 Diabetes Mellitus in Asia: A Systematic Review of Randomized Controlled Trials
Dahal, P. K., Rawal, L. B., Mahumud, R. A., Paudel, G., Sugishita, T., & Vandelanotte, C. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191710799 · Cited by 20
Dostarlimab for recurrent mismatch repair‐deficient endometrial cancer: A cost‐effectiveness study
Dioun, S. M., Chen, L., Melamed, A., Gockley, A. A., Clair, C. M. S., Hou, J. Y., Khoury‐Collado, F., Hur, C., Elkin, E. B., Accordino, M. K., et al. (2022) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.17338 · Cited by 20
Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China
Wu, W., Ding, S., Mingming, Z., Zhou, Y., Sun, X., Zhao, Z., Yang, Y., Hu, Y., & Dong, H. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2207742 · Cited by 22
Cost-utility, cost-effectiveness, and budget impact of Internet-based cognitive behavioral therapy for breast cancer survivors with treatment-induced menopausal symptoms
Verbeek, J. G. E., Atema, V., Mewes, J. C., van Leeuwen, M., Oldenburg, H. S. A., van Beurden, M., Hunter, M. S., van Harten, W. H., Aaronson, N. K., & Retèl, V. P. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05410-w · Cited by 22
Cost-effectiveness of integrating postpartum antiretroviral therapy and infant care into maternal & child health services in South Africa
Dugdale, C. M., Phillips, T. K., Myer, L., Hyle, E. P., Brittain, K., Freedberg, K. A., Cunnama, L., Walensky, R. P., Zerbe, A., Weinstein, M. C., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225104 · Cited by 20
Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis
Brito, N. C., de Assis, T. S. M., Rabello, A., & Cota, G. (2019) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0007856 · Cited by 20
Determination of the costs of falls in the older people according to the decision tree model
KUNDAKÇI, G. A., Yilmaz, M. C., & Sözmen, M. K. (2019) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2019.104007 · Cited by 20
The Video intervention to Inspire Treatment Adherence for Life (VITAL Start): protocol for a multisite randomized controlled trial of a brief video-based intervention to improve antiretroviral adherence and retention among HIV-infected pregnant women in Malawi
Kim, M. H., Tembo, T. A., Mazenga, A. C., Yu, X., Myer, L., Sabelli, R. A., Flick, R. J., Hartig, M., Wetzel, E., Simon, K., et al. (2020) · Trials · doi:10.1186/s13063-020-4131-8 · Cited by 20
Cost-effectiveness of a Novel Lipoarabinomannan Test for Tuberculosis in Patients With Human Immunodeficiency Virus
Reddy, K. P., Denkinger, C. M., Broger, T., McCann, N. C., Gupta‐Wright, A., Kerkhoff, A. D., Pei, P. P., Shebl, F. M., Fielding, K., Nicol, M. P., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1698 · Cited by 20
Screening for Tuberculosis Among Adults Newly Diagnosed With HIV in Sub-Saharan Africa
Zwerling, A. A., Sahu, M., Ngwira, L. G., Khundi, M., Harawa, T., Corbett, E. L., Chaisson, R. E., & Dowdy, D. W. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000712 · Cited by 20
Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer
Aguiar, P. N., Tan, P. S., Simko, S., Barreto, C. M. N., Gutierres, B. D. S., del Giglio, A., & Lopes, G. D. L., Jr. (2019) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2019gs4414 · Cited by 19
Seasonal influenza vaccination in Kenya: an economic evaluation using dynamic transmission modelling
Dawa, J., Emukule, G. O., Barasa, E., Widdowson, M., Anzala, O. A., van Leeuwen, E., Baguelin, M., Chaves, S. S., & Eggo, R. M. (2020) · BMC Medicine · doi:10.1186/s12916-020-01687-7 · Cited by 19
Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer
Lemmon, C. A., Zabor, E. C., & Pennell, N. A. (2022) · The Oncologist · doi:10.1093/oncolo/oyac021 · Cited by 20
Cost-Effectiveness Threshold for Healthcare: Justification and Quantification
Yanovskiy, K. M., Levy, O. N., Shaki, Y. Y., Zigdon, A., & Socol, Y. (2022) · INQUIRY The Journal of Health Care Organization Provision and Financing · doi:10.1177/00469580221081438 · Cited by 19
Cost-Effectiveness Analysis in Radiology: A Systematic Review
Zhou, A. L., Yousem, D. M., & Alvin, M. D. (2018) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2018.06.018 · Cited by 19
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy
Terpos, E., Jamotte, A., Christodoulopoulou, A., Campioni, M., Bhowmik, D., Kennedy, L., & Willenbacher, W. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1606002 · Cited by 20
Cost-effectiveness of childhood pneumococcal vaccination program in Ethiopia: results from a quasi-experimental evaluation
Kebede, T. T., Svensson, M., Addissie, A., Trollfors, B., & Andersson, R. (2019) · BMC Public Health · doi:10.1186/s12889-019-7423-8 · Cited by 19
Potential health impact and cost-effectiveness of bivalent human papillomavirus (HPV) vaccination in Afghanistan
Anwari, P., Debellut, F., Vodicka, E. L., Clark, A. D., Farewar, F., Zhwak, Z. A., Nazary, D., Pecenka, C. J., LaMontagne, D. S., & Safi, N. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.12.013 · Cited by 19
Venous thromboembolic events in inflammatory bowel diseases: A review of current evidence and guidance on risk in the post-hospitalization setting
Murthy, S. K., McCurdy, A. B. R., Carrier, M., & McCurdy, J. D. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.06.005 · Cited by 19
Challenges in Assessing the Cost-Effectiveness of Newborn Screening: The Example of Congenital Adrenal Hyperplasia
Grosse, S. D., & Vliet, G. V. (2020) · International Journal of Neonatal Screening · doi:10.3390/ijns6040082 · Cited by 19
Cost-effectiveness analysis of flucytosine as induction therapy in the treatment of cryptococcal meningitis in HIV-infected adults in South Africa
Miot, J., Leong, T. D. D., Takuva, S. G., Parrish, A., & Dawood, H. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-06268-9 · Cited by 19
National Methodological Guidelines to Conduct Budget Impact Analysis for Health Technology Assessment in India
Prinja, S., Chugh, Y., Rajsekar, K., & Muraleedharan, V. R. (2021) · Applied Health Economics and Health Policy · doi:10.1007/s40258-021-00668-y · Cited by 19
Cost-effectiveness of seasonal influenza vaccination in pregnant women, healthcare workers and adults >= 60 years of age in Lao People’s Democratic Republic
Ortega‐Sanchez, I. R., Mott, J. A., Kittikraisak, W., Khanthamaly, V., McCarron, M., Keokhonenang, S., Ounaphom, P., Pathammavong, C., Phounphenghack, K., Sayamoungkhoun, P., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.11.011 · Cited by 19
Comparison of clinical outcomes and cost-utility between unilateral biportal endoscopic discectomy and percutaneous endoscopic interlaminar discectomy for single-level lumbar disc herniation: a retrospective matched controlled study
Yang, Y., Yu, J.-C., Zhu, Z., Li, Y., Xiao, Z., Zhi, C.-G., Xie, Z., Kang, Y.-J., Li, J., & Zhou, B. (2024) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-024-05231-8 · Cited by 18
Improving Maternal Care through a State-Wide Health Insurance Program: A Cost and Cost-Effectiveness Study in Rural Nigeria
Gomez, G. B., Foster, N., Brals, D., Nelissen, H. E., Bolarinwa, O. A., Hendriks, M. E., Boers, A. C., van Eck, D., Rosendaal, N. T. A., Adenusi, P., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139048 · Cited by 20
Assessing the Cost-Utility of Universal Hepatitis B Vaccination Among Adults
Hall, E. W., Weng, M. K., Harris, A. M., Schillie, S. F., Nelson, N. P., Ortega‐Sanchez, I. R., Rosenthal, E. M., Sullivan, P. S., Lopman, B. A., Jones, J. S., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac088 · Cited by 19
Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges
Espinosa, O., Lesmes, P. A. R., Romano, G., Orozco, E., Basto, S., Ávila, D., Mesa, L., & Enríquez, H. D. (2024) · Applied Health Economics and Health Policy · doi:10.1007/s40258-024-00900-5 · Cited by 18
Economic and epidemiologic impact of guidelines for early ART initiation irrespective of CD4 count in Spain
Kasaie, P., Radford, M., Kapoor, S., Jung, Y., Novoa, B. H., Dowdy, D. W., & Shah, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206755 · Cited by 18
Economic Evaluation of Exercise-Based Fall Prevention Programs for People with Parkinson's Disease: A Systematic Review
Winser, S. J., Paul, L. F., Magnus, L. K. L., Szeto, Y., Shenug, T. P., Sing, Y. M., & Cheing, G. L. Y. (2019) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2019.0148 · Cited by 18
Economic evaluations of human schistosomiasis interventions: a systematic review and identification of associated research needs
Turner, H. C., French, M. D., Montresor, A., King, C. H., Rollinson, D., & Toor, J. (2020) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15754.2 · Cited by 28
Oxycodone versus morphine for cancer pain titration: A systematic review and pharmacoeconomic evaluation
Zhou, J., Wang, Y., & Jiang, G. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231763 · Cited by 20
Cost-Effectiveness Analysis of Prostate Health Index in Decision Making for Initial Prostate Biopsy
Huang, D., Yang, X., Wu, Y., Lin, X., Xu, D., Na, R., & Xu, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.565382 · Cited by 18
The Benefits and Costs of a Child Allowance
Garfinkel, I., Sariscsany, L., Ananat, E., Collyer, S. M., Hartley, R. P., Wang, B., & Wimer, C. (2022) · Journal of Benefit-Cost Analysis · doi:10.1017/bca.2022.15 · Cited by 46
Cost-effectiveness and cost-utility analysis of OTC use of simvastatin 10 mg for the primary prevention of myocardial infarction in Iranian men
Amirsadri, M., & Hassani, A. (2015) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/s40199-015-0129-2 · Cited by 18
Cost-effectiveness analysis of introducing universal childhood rotavirus vaccination in Bangladesh
Sarker, A. R., Sultana, M., Mahumud, R. A., Meer, R. V. D., & Morton, A. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1356962 · Cited by 18
Optimal Vaccine Subsidies for Endemic and Epidemic Diseases
Goodkin-Gold, M., Kremer, M. R., Snyder, C., & Williams, H. (2020) · National Bureau of Economic Research · doi:10.3386/w28085 · Cited by 18
COst–Effectiveness and Budget Impact of Lung Cancer Immunotherapy in South America: Strategies to Improve Access
Aguiar, P. N., del Giglio, A., Perry, L. A., Penny‐Dimri, J. C., Babiker, H. M., Tadokoro, H., Lopes, G. D. L., Jr., & de Mello, R. A. (2018) · Immunotherapy · doi:10.2217/imt-2017-0183 · Cited by 17
Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China
Dai, Z., Wong, I. O., Xie, C., Xu, W., Xiang, Y., Peng, L., & Lau, E. H. Y. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.06.024 · Cited by 17
Improving the Efficiency of the HIV/AIDS Policy Response: A Guide to Resource Allocation Modeling
Kahn, J. G., Bollinger, L. A., Stover, J., & Marseille, E. A. (2017) · World Bank, Washington, DC eBooks · doi:10.1596/978-1-4648-0524-0_ch9 · Cited by 17
Self-citation
Public health impact and cost-effectiveness of rotavirus vaccination in China: Comparison between private market provision and national immunization programs
Wang, J., Zhang, H., Zhang, H., & Fang, H. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2090162 · Cited by 17
First-line Immuno-chemotherapy for extensive-stage small-cell lung cancer: A network meta-analysis and cost-effectiveness analysis
Zhu, Y., Liu, K., Yang, Q., Zeng, M., & Peng, L. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1028202 · Cited by 17
Partners-based HIV treatment for seroconcordant couples attending antenatal and postnatal care in rural Mozambique: A cluster randomized trial protocol
Audet, C. M., Graves, E., Barreto, E., Schacht, C. D., Gong, W., Shepherd, B. E., Aboobacar, A., Gonzaléz‐Calvo, L., Alvim, M. F. S., Aliyu, M. H., et al. (2018) · Contemporary Clinical Trials · doi:10.1016/j.cct.2018.05.020 · Cited by 17
Effects of geographic and economic heterogeneity on rotavirus diarrhea burden and vaccination impact and cost-effectiveness in the Lao People’s Democratic Republic
Rheingans, R., Anderson, J. D., Bagamian, K. H., & Pecenka, C. J. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.02.009 · Cited by 17
Accounting for consumers’ preferences in the analysis of dietary recommendations
Cobiac, L. J., Irz, X., Leroy, P. L., Réquillart, V., Scarborough, P., & Soler, L. G. (2018) · European Journal of Clinical Nutrition · doi:10.1038/s41430-018-0317-5 · Cited by 17
Protocol for evaluation of enhanced models of primary care in the management of stroke and other chronic disease (PRECISE)
Andrew, N. E., Kim, J., Cadilhac, D. A.-M., Sundararajan, V., Thrift, A. G., Churilov, L. P., Lannin, N. A., Srikanth, V. K., & Kilkenny, M. F. (2019) · International Journal for Population Data Science · doi:10.23889/ijpds.v4i1.1097 · Cited by 17
Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR + breast cancer and negative axillary ultrasound
McEvoy, A. M., Poplack, S. P., Nickel, K. B., Olsen, M. A. A., Ademuyiwa, F. O., Zoberi, I., Odom, E. B., Yu, J. S., Chang, S., & Gillanders, W. E. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05768-2 · Cited by 17
Cost-effectiveness modelling to optimise active screening strategy for gambiense human African trypanosomiasis in endemic areas of the Democratic Republic of Congo
Davis, C. N., Rock, K. S., Antillón, M., Miaka, E. M., & Keeling, M. J. (2021) · BMC Medicine · doi:10.1186/s12916-021-01943-4 · Cited by 17
Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis
Janko, M., Joffe, J., Michael, D., Earl, L., Rosettie, K. L., Sparks, G. W., Albertson, S. B., Compton, K., Pedroza, P., Stafford, L. K., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.042 · Cited by 17
The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa
Knight, G. M., Gomez, G. B., Dodd, P. J., Dowdy, D. W., Zwerling, A. A., Wells, W. A., Cobelens, F. G. J., Vassall, A., & White, R. G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145796 · Cited by 17
Health system support and health system strengthening: two key facilitators to the implementation of ambulatory tuberculosis treatment in Uzbekistan
Kohler, S., Asadov, D. A., Bründer, A., Healy, S., Khamraev, A. K., Sergeeva, N. M., & Tinnemann, P. (2016) · Health Economics Review · doi:10.1186/s13561-016-0100-z · Cited by 17
A systematic review of health economic evaluations of vaccines in Brazil
Sartori, A. M. C., Rozman, L. M., Decimoni, T. C., Leandro, R., Novaes, H. M. D., & de Soárez, P. C. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1282588 · Cited by 16
Cost-Utility Analysis of Continuous Ambulatory Peritoneal Dialysis and Automated Peritoneal Dialysis for Thai Patients With End-Stage Renal Disease
Thaweethamcharoen, T., Sritippayawan, S., Noparatayaporn, P., & Aiyasanon, N. (2020) · Value in Health Regional Issues · doi:10.1016/j.vhri.2019.10.004 · Cited by 16
Cost-effectiveness analysis of human-centred design for global health interventions: a quantitative framework
Liu, C., Lee, J. H., Gupta, A. J., Tucker, A., Larkin, C., Turimumahoro, P., Katamba, A., Davis, J. L., & Dowdy, D. W. (2022) · BMJ Global Health · doi:10.1136/bmjgh-2021-007912 · Cited by 16
Cost-Effectiveness Analysis
Lauer, J. A., Morton, A., & Bertram, M. (2019) · doi:10.1093/oso/9780190912765.003.0005 · Cited by 16
Cost-effectiveness of extracorporeal cardiopulmonary resuscitation for refractory out-of-hospital cardiac arrest: A modelling study
Doan, T. N., Rashford, S., Pincus, J. M., & Bosley, E. (2022) · Resuscitation Plus · doi:10.1016/j.resplu.2022.100309 · Cited by 16
What are the impacts of increasing cost-effectiveness Threshold? a protocol on an empirical study based on economic evaluations conducted in Thailand
Isaranuwatchai, W., Nakamura, R., Wee, H. L., Sarajan, M. H., Wang, Y., Soboon, B., Lou, J., Chai, J. H., Theantawee, W., Laoharuangchaiyot, J., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274944 · Cited by 16
Cost-effectiveness analysis of first-line sintilimab plus chemotherapy vs. chemotherapy alone for unresectable advanced or metastatic gastric or gastroesophageal junction cancer in China
Xiang, Z., Ma, L., Fu, Y., & Pan, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1411571 · Cited by 16
The Cost-Effectiveness of Pregabalin Versus Gabapentin for Peripheral Neuropathic Pain (pNeP) and Postherpetic Neuralgia (PHN) in China
Wang, B. C. M., Liu, D., Furnback, W. E., Bifa, F., Dong, P., Xie, L., Guzauskas, G. F., & Zhang, S. (2016) · Pain and Therapy · doi:10.1007/s40122-016-0048-z · Cited by 16
Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review
Younis, T., Rayson, D., Jovanovic, S., & Skedgel, C. D. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3954-1 · Cited by 16
Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia
Loganathan, T., Ng, C., Lee, W. S., Hutubessy, R. C. W., Verguet, S., & Jit, M. (2017) · Health Policy and Planning · doi:10.1093/heapol/czx166 · Cited by 16
A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia
Lee, J.-S., Lourenço, J., Gupta, S., & Farlow, A. W. K. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.03.002 · Cited by 16
An empirical assessment of the Healthy Early Childhood Program in Rio Grande do Sul State, Brazil
Ribeiro, F. G., Braun, G., Carraro, A., Teixeira, G. D. S., & Gigante, D. P. (2018) · Cadernos de Saúde Pública · doi:10.1590/0102-311x00027917 · Cited by 17
The impact and cost-effectiveness of user fee exemption by contracting out essential health package services in Malawi
Zeng, W., Sun, D., Mphwanthe, H., Huan, T., Nam, J. E., Saint-Firmin, P., Manthalu, G., Sharma, S., & Dutta, A. (2019) · BMJ Global Health · doi:10.1136/bmjgh-2018-001286 · Cited by 15
Impact of Making Dental Care Affordable on Quality of Life in Adults Aged 45 Years and Older
Naavaal, S., Griffin, S. O., & Jones, J. A. (2019) · Journal of Aging and Health · doi:10.1177/0898264319857967 · Cited by 16
Short- and long-term safety and efficacy of bariatric surgery for severely obese adolescents: a narrative review
Sarno, L. A., Lipshultz, S. E., Harmon, C. M., Cruz-Munoz, N. F. D. L., & Balakrishnan, P. L. (2019) · Pediatric Research · doi:10.1038/s41390-019-0532-3 · Cited by 17

Authors: Marseille, E., Larson, B., Kazi, D. S., Kahn, J. G., & Rosen, S.
Affiliations: Health Strategies International, 555 Fifty-ninth Street, Oakland, California, 94609, United States of America (USA).
Boston University (US)
San Francisco General Hospital (US)
University of California, San Francisco (US)
Corresponding author: Marseille, Elliot
ORCID: Marseille, Elliot
Larson, Bruce
Kazi, Dhruv S
Kahn, James G
Rosen, Sydney
Venue: Bulletin of the World Health Organization
Publisher: WHO Press
Published: 2014-12-15
Volume: 93
Issue: 2
Pages: 118-124
ISSN: 0042-9686 (ISSN-L)
DOI: 10.2471/blt.14.138206
PMC: PMC4339959
OpenAlex: W2133104890
Cited by: 851
References: 42
Citations by year: 2026: 45 · 2025: 68 · 2024: 58 · 2023: 69 · 2022: 93 · 2021: 101 · 2020: 100 · 2019: 105 · 2018: 76 · 2017: 78 · 2016: 40 · 2015: 18
FWCI: 112.73
Type: journal article
Language: en
Open access: diamond
doi.org
Licence: cc-by
Locations: Bulletin of the World Health Organization (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Institute of Mental Health (P30MH062246)
National Institute on Drug Abuse (R01DA015612)
Topics: Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Global Health Care Issues
Keywords: cost-effectiveness threshold, WHO-CHOICE, disability-adjusted life years, GDP per capita, healthcare resource allocation, public health decision-making, affordability, cost-effectiveness analysis
MeSH terms: Cost-Benefit Analysis, Developing Countries, Female, Health Priorities, Humans, Pregnancy, Syphilis, Global Health, World Health Organization, HIV Infections, Quality-Adjusted Life Years, Benchmarking, Anti-Retroviral Agents, Insecticide-Treated Bednets, Gross Domestic Product

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Thresholds for the cost–effectiveness of interventions: alternative approaches

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks